AP9801234A0 - Cox-2 selective carprofenor treating pain and inflammation in dogs. - Google Patents
Cox-2 selective carprofenor treating pain and inflammation in dogs.Info
- Publication number
- AP9801234A0 AP9801234A0 APAP/P/1998/001234A AP9801234A AP9801234A0 AP 9801234 A0 AP9801234 A0 AP 9801234A0 AP 9801234 A AP9801234 A AP 9801234A AP 9801234 A0 AP9801234 A0 AP 9801234A0
- Authority
- AP
- ARIPO
- Prior art keywords
- cox
- acids
- activity
- dogs
- inhibition
- Prior art date
Links
- 101150071146 COX2 gene Proteins 0.000 title abstract 3
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 title abstract 3
- 101150000187 PTGS2 gene Proteins 0.000 title abstract 3
- 241000282472 Canis lupus familiaris Species 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 4
- 230000005764 inhibitory process Effects 0.000 abstract 3
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 abstract 2
- 101150062589 PTGS1 gene Proteins 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 150000007513 acids Chemical class 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 abstract 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 abstract 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 abstract 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 1
- 235000011054 acetic acid Nutrition 0.000 abstract 1
- PDODBKYPSUYQGT-UHFFFAOYSA-N acetic acid;1h-indene Chemical class CC(O)=O.C1=CC=C2CC=CC2=C1 PDODBKYPSUYQGT-UHFFFAOYSA-N 0.000 abstract 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- PUXBGTOOZJQSKH-UHFFFAOYSA-N carprofen Chemical compound C1=C(Cl)C=C2C3=CC=C(C(C(O)=O)C)C=C3NC2=C1 PUXBGTOOZJQSKH-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- -1 heteroaryl acetic acids Chemical class 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 abstract 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Treating or preventing inflammatory processes and diseases in dogs associated with the activity of inducible cyclo-oxygenase-2 (cox-2), while at the same time reducing or eliminating undesirable side effects associated with simultaneous inhibition of the activity of constitutive cyclo-oxygenase-1 (cox-1)by selectively inhibiting cox-2:cox-1 activity inhibition is at least 3:1 based on ex vivo inhibition levels measured in whole blood;the inhibitor is a member selected from the froup of anti-inflammatory compounds consisting essentially of salicylic acid derivatives,p-aminophenol derivatives, indole and indene acetic acids, heteroaryl acetic acids, arylpropionic acids, anthranilic acids, enolic acids, and alkanones; the inhibitor in particular is comprised of (+)(s)-enantiomer of 6-chloro-alpha-methyl-9h-carbazole-2-acetic acid.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4563597P | 1997-05-05 | 1997-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP9801234A0 true AP9801234A0 (en) | 1999-11-04 |
Family
ID=21939053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1998/001234A AP9801234A0 (en) | 1997-05-05 | 1998-05-04 | Cox-2 selective carprofenor treating pain and inflammation in dogs. |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP0988034A1 (en) |
| JP (1) | JP2000513020A (en) |
| KR (2) | KR20010012300A (en) |
| CN (1) | CN1255059A (en) |
| AP (1) | AP9801234A0 (en) |
| AR (2) | AR011726A1 (en) |
| AU (1) | AU6932198A (en) |
| BG (1) | BG103852A (en) |
| BR (1) | BR9808720A (en) |
| CA (1) | CA2288759A1 (en) |
| DZ (1) | DZ2479A1 (en) |
| EA (1) | EA003696B1 (en) |
| GT (1) | GT199800063A (en) |
| HR (1) | HRP980244A2 (en) |
| HU (1) | HUP0001286A3 (en) |
| ID (1) | ID21311A (en) |
| IL (1) | IL132570A0 (en) |
| IS (1) | IS5220A (en) |
| MA (1) | MA26491A1 (en) |
| NO (1) | NO995389L (en) |
| NZ (1) | NZ500183A (en) |
| OA (1) | OA11213A (en) |
| PA (1) | PA8450601A1 (en) |
| PE (1) | PE72599A1 (en) |
| PL (1) | PL337003A1 (en) |
| SK (1) | SK148199A3 (en) |
| TN (1) | TNSN98059A1 (en) |
| TW (1) | TW590773B (en) |
| UY (1) | UY24989A1 (en) |
| WO (1) | WO1998050033A1 (en) |
| YU (1) | YU55899A (en) |
| ZA (1) | ZA983722B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245797B1 (en) | 1997-10-22 | 2001-06-12 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease |
| AU2003204888B2 (en) * | 1998-05-22 | 2005-07-28 | Pfizer Products Inc. | Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives |
| US6506785B2 (en) * | 1998-05-22 | 2003-01-14 | Pfizer, Inc. | Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives |
| WO2000024393A1 (en) * | 1998-10-23 | 2000-05-04 | Merck Frosst Canada & Co. | Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use |
| DE60023119T2 (en) * | 1999-03-10 | 2006-07-20 | G.D. Searle Llc | COMPOSITIONS FOR THE ADMINISTRATION OF A CYCLOOXYGENASE-2 HEMMER TO ANIMALS |
| AU1592901A (en) * | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| WO2001087343A2 (en) * | 2000-05-15 | 2001-11-22 | Merck Frosst Canada & Co. | Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| EA011309B1 (en) | 2000-06-13 | 2009-02-27 | Вайет | COMPOSITIONS FOR WEAKENING OF PAINS CONTAINING CELCOXIB |
| DE10032132A1 (en) * | 2000-07-01 | 2002-01-17 | Lohmann Therapie Syst Lts | Dermal therapeutic system containing non-steroidal anti-inflammatory drugs with selective COX-2 inhibition |
| ATE421595T1 (en) | 2000-08-07 | 2009-02-15 | Univ Vanderbilt | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING COX-2 ACTIVITY AND 2-ARACHIDONYLGLYCERIN METABOLITES |
| AU2002354901A1 (en) * | 2001-07-16 | 2003-03-03 | Edward Hogestatt | Compounds with analgesic, antipyretic and/or anti-inflammatory activity |
| EP1534305B9 (en) | 2003-05-07 | 2007-03-07 | Osteologix A/S | Treating cartilage / bone conditions with water-soluble strontium salts |
| BRPI0412581A (en) * | 2003-07-31 | 2006-09-19 | Pharmacia & Upjohn Co Llc | dispersible formulation of an anti-inflammatory agent |
| EP1940380A2 (en) * | 2005-05-20 | 2008-07-09 | Pfizer Limited | Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-2 delta-ligands |
| CN103120653B (en) | 2007-04-04 | 2015-09-30 | 希格默伊德药业有限公司 | A kind of combination of oral medication |
| US8951570B2 (en) | 2007-04-26 | 2015-02-10 | Sigmoid Pharma Limited | Manufacture of multiple minicapsules |
| PL2471518T3 (en) | 2009-05-18 | 2018-01-31 | Sigmoid Pharma Ltd | Composition comprising oil drops |
| BR112012002963A2 (en) | 2009-08-12 | 2017-10-24 | Sigmoid Pharma Ltd | immunomodulatory compositions comprising a polymer matrix and an oil phase |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| US12109218B2 (en) | 2014-12-09 | 2024-10-08 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| PL3113774T3 (en) | 2014-03-06 | 2022-06-13 | Elanco Animal Health Incorporated | Compositions of grapiprant and methods for using the same |
| PL3215127T3 (en) | 2014-11-07 | 2021-05-17 | Sublimity Therapeutics Limited | Compositions comprising cyclosporin |
| CN107106536A (en) * | 2015-01-09 | 2017-08-29 | 美洲豹动物健康公司 | The method for treating the diarrhoea of companion animals |
| US20230174485A1 (en) * | 2020-03-25 | 2023-06-08 | Sri International | Lipoxygenase inhibitors |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| KR102404883B1 (en) | 2020-11-30 | 2022-06-07 | (주)이노보테라퓨틱스 | Pharmaceutical composition for preventing or treating keloid or hypertrophic scar comprising Benzbromarone |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896145A (en) * | 1972-07-24 | 1975-07-22 | Hoffmann La Roche | Carbazoles |
| CA1319886C (en) * | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
-
1998
- 1998-03-02 DZ DZ980089A patent/DZ2479A1/en active
- 1998-04-30 TW TW087106689A patent/TW590773B/en not_active IP Right Cessation
- 1998-05-01 YU YU55899A patent/YU55899A/en unknown
- 1998-05-01 CN CN98804845A patent/CN1255059A/en active Pending
- 1998-05-01 IL IL13257098A patent/IL132570A0/en unknown
- 1998-05-01 PL PL98337003A patent/PL337003A1/en unknown
- 1998-05-01 ID IDP980651A patent/ID21311A/en unknown
- 1998-05-01 SK SK1481-99A patent/SK148199A3/en unknown
- 1998-05-01 JP JP10547869A patent/JP2000513020A/en active Pending
- 1998-05-01 BR BR9808720-7A patent/BR9808720A/en not_active IP Right Cessation
- 1998-05-01 NZ NZ500183A patent/NZ500183A/en unknown
- 1998-05-01 KR KR1019997010252A patent/KR20010012300A/en not_active Ceased
- 1998-05-01 WO PCT/IB1998/000662 patent/WO1998050033A1/en not_active Ceased
- 1998-05-01 CA CA002288759A patent/CA2288759A1/en not_active Abandoned
- 1998-05-01 HU HU0001286A patent/HUP0001286A3/en unknown
- 1998-05-01 KR KR10-2003-7005258A patent/KR20040004406A/en not_active Ceased
- 1998-05-01 AU AU69321/98A patent/AU6932198A/en not_active Abandoned
- 1998-05-01 EA EA199900895A patent/EA003696B1/en not_active IP Right Cessation
- 1998-05-01 EP EP98915041A patent/EP0988034A1/en not_active Withdrawn
- 1998-05-04 PE PE1998000335A patent/PE72599A1/en not_active Application Discontinuation
- 1998-05-04 AP APAP/P/1998/001234A patent/AP9801234A0/en unknown
- 1998-05-04 UY UY24989A patent/UY24989A1/en not_active Application Discontinuation
- 1998-05-04 MA MA25059A patent/MA26491A1/en unknown
- 1998-05-04 GT GT199800063A patent/GT199800063A/en unknown
- 1998-05-04 ZA ZA9803722A patent/ZA983722B/en unknown
- 1998-05-04 TN TNTNSN98059A patent/TNSN98059A1/en unknown
- 1998-05-05 HR HR60/045,635A patent/HRP980244A2/en not_active Application Discontinuation
- 1998-05-05 AR ARP980102089A patent/AR011726A1/en unknown
- 1998-05-05 PA PA19988450601A patent/PA8450601A1/en unknown
-
1999
- 1999-10-19 IS IS5220A patent/IS5220A/en unknown
- 1999-11-02 OA OA9900242A patent/OA11213A/en unknown
- 1999-11-03 BG BG103852A patent/BG103852A/en unknown
- 1999-11-04 NO NO995389A patent/NO995389L/en not_active Application Discontinuation
-
2003
- 2003-04-09 AR ARP030101251A patent/AR039628A2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP9801234A0 (en) | Cox-2 selective carprofenor treating pain and inflammation in dogs. | |
| HK1040198A1 (en) | Gabapentin derivative for preventing and treating visceral pain | |
| NZ330860A (en) | Method of inhibiting photoaging of skin | |
| EE04416B1 (en) | Use of α1L agonists for the treatment of urinary incontinence | |
| EA200000825A1 (en) | COMPOSITION INCLUDING IL-1 INHIBITOR AND POLYMER MONITORING THE LIBERATION | |
| BG104476A (en) | Therapeutical form for tolterodin with controlled release | |
| WO2000028980A3 (en) | Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain | |
| DE50014190D1 (en) | USE OF PHTHALAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
| NO985575L (en) | Methods and Preparations Useful for Inhibiting <alfa> v <beta> 5-Mediated Angiogenesis | |
| BR9908564A (en) | Absorbent article and process to reduce the activity of proteolytic enzymes of a fecal protease present in the same | |
| NO2006007I1 (en) | (+) - (S) -2- (3-benzoylphenyl) propionic acid tromethamine salt (deksketoprofentrometamol) | |
| ATE527022T1 (en) | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT AND PREVENTION OF TUMORS, TUMOR-DEPENDENT DISEASES AND CACHEXIA | |
| AU3772000A (en) | Selective inhibition of cyclooxygenase-2 | |
| EP1098642A4 (en) | METHOD FOR TREATING CONDITIONS MODULATED BY LACTOSYLCERAMIDES | |
| AU3346095A (en) | Use of 5-substituted pyridine and hexahydroquinoline-3 carboxylic acid derivatives for treating diseases of the central nervous system | |
| AU8026200A (en) | Treatment of heart disease with cox-2 inhibitors | |
| DK0782441T3 (en) | Pharmaceutical control of inflammation | |
| IL143594A0 (en) | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases | |
| AU6330799A (en) | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | |
| CO5021216A1 (en) | SELECTIVE CARPROPHENE FOR COX-2, FOR THE TREATMENT OF PAIN AND INFLAMMATION IN DOGS | |
| EP0330218A3 (en) | Inhibitors of lysyl oxidase | |
| EE9700350A (en) | New use of COMT inhibitors and a method for preventing diabetic vascular disorders | |
| ATE286892T1 (en) | HYDROXAM AND CARBOXYLIC ACID DERIVATIVES WITH MMP AND TNF INHIBITING ACTIVITY | |
| NO20001812L (en) | Bile acid salts of metals with physiological effect, as well as their therapeutic use | |
| BR0213634A (en) | Delayed-acting drug delivery system for an antispasmodic agent |